192 related articles for article (PubMed ID: 35580945)
1. Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma.
Hopkins DT; Waters D; Manecksha RP; Lynch TH
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35580945
[TBL] [Abstract][Full Text] [Related]
2. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
3. Role of Surgery in Metastatic Renal Cell Carcinoma.
Nolazco JI; Chang SL
Hematol Oncol Clin North Am; 2023 Oct; 37(5):893-905. PubMed ID: 37330346
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
5. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
6. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
[TBL] [Abstract][Full Text] [Related]
7. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
8. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
Meza L; Chehrazi-Raffle A; Pal SK
Curr Opin Urol; 2020 Sep; 30(5):740-742. PubMed ID: 32732626
[No Abstract] [Full Text] [Related]
12. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?
Kokorovic A; Rendon RA
Curr Opin Support Palliat Care; 2019 Sep; 13(3):255-261. PubMed ID: 31082942
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.
Soares A; Maia MC; Vidigal F; Marques Monteiro FS
Oncology; 2020; 98(1):1-9. PubMed ID: 31514196
[TBL] [Abstract][Full Text] [Related]
14. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
[TBL] [Abstract][Full Text] [Related]
15. [Synchronous oligometastatic renal cell carcinoma-what is the role of surgery?].
Ivanyi P; Kuczyk M
Urologe A; 2021 Dec; 60(12):1546-1554. PubMed ID: 34738151
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
[TBL] [Abstract][Full Text] [Related]
17. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.
Abel EJ; Carrasco A; Culp SH; Matin SF; Tamboli P; Tannir NM; Wood CG
BJU Int; 2012 Dec; 110(11):1742-6. PubMed ID: 22503066
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.
Faba OR; Brookman-May SD; Linares E; Breda A; Pisano F; Subiela JD; Sanguedolce F; Brausi M; Palou J
World J Urol; 2017 Dec; 35(12):1807-1816. PubMed ID: 28702843
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
[TBL] [Abstract][Full Text] [Related]
20. Choice of Surgical Options in Kidney Cancer and Surgical Complications.
Wasserman M; Sobel D; Pareek G
Semin Nephrol; 2020 Jan; 40(1):42-48. PubMed ID: 32130965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]